---
title: "《盈喜》泰格醫藥預告去年盈利增 105%-204%"
description: "泰格醫藥預計 2025 年度盈利將增長 105%-204%，介乎 8.3 億至 12.3 億人民幣。公司非流動金融資產處置及收益大幅提升，新簽訂單數量和金額均實現增長，全年淨新增訂單預計在 95 億至 105 億人民幣之間，營業收入預計為 66.6 億至 76.8 億人民幣，增長 1%-16%。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274177703.md"
published_at: "2026-01-29T16:01:45.000Z"
---

# 《盈喜》泰格醫藥預告去年盈利增 105%-204%

> 泰格醫藥預計 2025 年度盈利將增長 105%-204%，介乎 8.3 億至 12.3 億人民幣。公司非流動金融資產處置及收益大幅提升，新簽訂單數量和金額均實現增長，全年淨新增訂單預計在 95 億至 105 億人民幣之間，營業收入預計為 66.6 億至 76.8 億人民幣，增長 1%-16%。

泰格醫藥 (03347.HK) 發盈喜，預計 2025 年度盈利介乎 8.3 億至 12.3 億人民幣，較上年度增長 105%-204%。年內，公司持有的非流動金融資產處置及持有收益大幅提升。同時，新簽訂單數量和金額均實現較好增長，全年淨新增訂單介乎 95 億至 105 億人幣，上年度錄得 84.2 億人民幣。

2025 年，營業收入 66.6 億至 76.8 億人民幣，上升 1%-16%，重回增長態勢。

### Related Stocks

- [516500.CN - 華夏中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [516930.CN - 生物科技ETF基金](https://longbridge.com/zh-HK/quote/516930.CN.md)
- [159837.CN - 易方達中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [300347.CN - 泰格醫藥](https://longbridge.com/zh-HK/quote/300347.CN.md)
- [516820.CN - 平安中證醫療創新ETF](https://longbridge.com/zh-HK/quote/516820.CN.md)
- [03347.HK - 泰格醫藥](https://longbridge.com/zh-HK/quote/03347.HK.md)
- [159849.CN - 招商中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159849.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/zh-HK/news/276549711.md) |
| Bioceltix Gets GMP Certificate For Wroclaw Veterinary Medicine Facility | Bioceltix :SAID ON TUESDAY IT OBTAINED A GMP CERTIFICATE FOR ITS WROCLAW FACILITY FROM THE MAIN PHARMACEUTICAL INSPECTOR | [Link](https://longbridge.com/zh-HK/news/276203122.md) |
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-HK/news/276024005.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-HK/news/276016059.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。